Dr. Sipko Mülder is a senior Dutch healthcare and regulatory affairs executive with extensive experience across pharmaceutical regulation, medicines assessment, healthcare supervision, and public policy. He currently serves as Secretary/Director of the Central Committee on Research Involving Human Subjects (CCMO), where he is responsible for supporting the committee’s statutory role in safeguarding the quality, consistency, and integrity of human subject research in the Netherlands.

Prior to joining the CCMO, Sipko was a management team member within the Directorate for Medicines and Medical Technology at the Dutch Ministry of Health, Welfare and Sport (VWS), focusing on innovation, regulatory policy, and the availability of medicines and medical technologies.

Earlier in his career, he held senior leadership positions at the Health and Youth Care Inspectorate (IGJ) and the Medicines Evaluation Board (CBG-MEB), where he led regulatory and pharmacotherapeutic assessment teams. He also gained experience in the pharmaceutical industry, including work associated with clinical development and medicines innovation.

Sipko studied Medical Biology at Vrije Universiteit Amsterdam and obtained his PhD at VU Medical Center. His career has been dedicated to strengthening the interface between science, regulation, clinical research, and public health, with a particular focus on ensuring that innovative medicines and technologies reach patients safely and efficiently.